Clinical trials: ARDS Associated With COVID-19
ARDS, Sars-CoV-2 Infection
Physiological Response to Prone Position in COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS)
Retrospective study in COVID-19 ARDS patients hospitalised in the ICU. Investigators aim to explore the effects of prone positioning on oxygenation, dead space ventilation and mortality.
- Trial name
- NCT05092737
- Testing
- Prone positioning
- Where
- Switzerland
- Volunteers
- 31 people
- Sponsor
- University of Lausanne Hospitals
COVID-19 Acute Respiratory Distress Syndrome
When to Apply to Which Patient in MSC?
Mesenchymal stem cell (MSC) therapy is among the promising treatments for acute respiratory distress syndrome (ARDS). Our study aimed to investigate the clinical efficacy of MSC treatment in COVID-19 patients, to determine when…
- Trial name
- MSC (NCT05240430)
- Testing
- Mesenchymal Stem Cell Antigen-1, Human
- Where
- Turkey (Türkiye)
- Volunteers
- 1 people
- Sponsor
- Trabzon Kanuni Education and Research Hospital
Covid19
A Phase 2b Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study, Evaluating Efficacy and Safety of Allocetra-OTS in Patients With Severe or Critical COVID-19 With Associated Acute Respiratory Distress Syndrome (ARDS)
This is a Phase 2b multi-center, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of intravenous (IV) Allocetra-OTS 10x10^9 cells vs placebo (1:1) in adult hospitalized patients with severe or…
- Trial name
- NCT04922957
- Testing
- ALLOCETRA-OTS
- Where
- Israel
- Volunteers
- 12 people
- Sponsor
- Enlivex Therapeutics Ltd.
COVID-19 Acute Respiratory Distress Syndrome, Respiratory Distress Syndrome
Safety and Effectiveness of Placental Derived Exosomes and Umbilical Cord Mesenchymal Stem Cells in Moderate to Severe Acute Respiratory Distress Syndrome (ARDS) Associated With the Novel Corona Virus Infection (COVID-19)
Recent advances have been made in prevention of the viral infection via vaccines but there is still need for effective treatment options for patients. Novel therapies need to be developed to further improve clinical outcomes.
- Trial name
- NCT05387278
- Testing
- EV-Pure™ and WJ-Pure™
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Vitti Labs, LLC
Acute Lung Injury (ALI) Associated With COVID-19, Lung Inflammation Associated With COVID-19
TD-0903 for ALI Associated With COVID-19
This Phase 2 study will evaluate the efficacy, safety, pharmacodynamics and pharmacokinetics of inhaled TD-0903 compared with a matching placebo in combination with standard of care (SOC) in hospitalized patients with confirmed…
- Trial name
- NCT04402866
- Testing
- TD-0903
- Where
- 24 sites in United States, Brazil and 5 more
- Volunteers
- 235 people
- Sponsor
- Theravance Biopharma
Systemic Inflammatory Response Syndrome
Cell Therapy With Treg Cells Obtained From Thymic Tissue (thyTreg) to Control the Immune Hyperactivation Associated With COVID-19 and/or Acute Respiratory Distress Syndrome (THYTECH2)
The investigators developed a GMP protocol to isolate Treg cells from thymic tissue (thyTreg). The thyTreg cells are being evaluated in a Phase I/II clinical trial to evaluate the safety and efficacy of the adoptive transfer of…
- Trial name
- THYTECH2 (NCT06052436)
- Testing
- Allogeneic thyTreg 5.000.000, Allogeneic thyTreg 10.000.000
- Where
- Spain
- Volunteers
- 24 people
- Sponsor
- Hospital General Universitario Gregorio Marañon
Acute Respiratory Distress Syndrome, Coronavirus
Prone Position Improves End-Expiratory Lung Volumes in COVID-19 Acute Respiratory Distress Syndrome
Covid-19 associated Acute Respiratory Distress Syndrome (ARDS) may present with profound hypoxemia not fully explained with pulmonary infiltrates.
- Conditions
- Acute Respiratory Distress Syndrome, Coronavirus, Mechanical Ventilation Complication, Ventilation Perfusion Mismatch
- Trial name
- NCT04818164
- Where
- Turkey (Türkiye)
- Volunteers
- 43 people
- Sponsor
- Istanbul University - Cerrahpasa
COVID-19
Study to Evaluate the Efficacy and Safety of Maraviroc in SARS-CoV-2 Infection (COVID-19).
This is a bicentric, phase 2, randomized, open-label study to evaluate the efficacy and safety of maraviroc associated with standard treatment in hospitalized patients with pulmonary SARS-CoV-2 infection (COVID-19).
- Trial name
- MARACOVID (NCT04441385)
- Testing
- Maraviroc 300 mg, Standard care therapy
- Where
- 2 sites in Spain
- Volunteers
- 60 people
- Sponsor
- Hospital Universitario Infanta Leonor
COVID-19-Associated Acute Respiratory Distress Syndrome (ARDS)
Clinical and Molecular Effects of N-Acetylcysteine Treatment in COVID-19-Related Acute Respiratory Distress Syndrome
Prospective, randomized, double-blind, placebo-controlled clinical trial evaluating the clinical and molecular effects of intravenous N-acetylcysteine (NAC) in patients with COVID-19-associated acute respiratory distress syndrome…
- Trial name
- A Prospective (NCT07374991)
- Testing
- N-Acetylcysteine (NAC)
- Where
- Turkey (Türkiye)
- Volunteers
- 59 people
- Sponsor
- University of Gaziantep
COVID-19 Acute Respiratory Distress Syndrome, Acute Kidney Injury Due to COVID-19
Acute Kidney Dysfunction in COVID-19 and Non-COVID-19 Related ARDS
In addition to respiratory involvement, SARS-CoV 2, the virus responsible for coronavirus 2019 or Covid-19, appears to be responsible for renal involvement such as acute renal failure or proteinuria, so the mechanisms are not…
- Trial name
- URICOV (NCT05699889)
- Testing
- Data collection
- Where
- France
- Volunteers
- 130 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
ARDS, COVID-19
ECMO for COVID-19 vs Influenza A H1N1 Associated ARDS
Objective: Veno-venous ECMO has been used as a rescue therapy for patients with severe ARDS associated to influenza A H1N1 and COVID19 viral pneumonia.
- Conditions
- ARDS, COVID-19, H1N1 Influenza
- Trial name
- InfluCOV_ECMO (NCT05080933)
- Where
- Italy
- Volunteers
- 308 people
- Sponsor
- University of Turin, Italy
Respiratory Distress Syndrome
Prone Positioning vs. Prone Positioning and NO Inhalation in COVID-19 ARDS.
The investigators aim to investigate the effects of prone positioning and prone positioning with NO inhalation for COVID-19 patients with ARDS.
- Trial name
- NCT05715788
- Testing
- Nitric oxide, prone positioning
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Zhongshan Hospital
Ards, Mechanical Ventilation Pressure High
Prognostic Value of Respiratory System Compliance Under VV-ECMO on 180-day Mortality in COVID-19 ARDS.
Mortality of patients with COVID-19 associated acute respiratory distress syndrome (CARDS) treated with veno-venous extra-corporal membrane oxygenation (vv-ECMO) is increasing over time since the beginning of the COVID-19…
- Conditions
- Ards, Mechanical Ventilation Pressure High, Extracorporeal Membrane Oxygenation
- Trial name
- COMPLIECMO (NCT05341687)
- Testing
- No applicable
- Where
- France
- Volunteers
- 122 people
- Sponsor
- Central Hospital, Nancy, France
COVID-19 Acute Respiratory Distress Syndrome, Influenza A
Treatment of Respiratory Complications Associated With COVID19,Influenza ,Metapneumovirus,RSV Infection Using ProTrans®
To investigate the safety and tolerance of a single infusion of ProTrans® in subjects with "severe" respiratory complications associated with pneumonia caused by COVID-19, Influenza A, Metapneumovirus or RSV infection.
- Conditions
- COVID-19 Acute Respiratory Distress Syndrome, Influenza A, Metapneumovirus Pneumonia, Respiratory Syncytial Virus (RSV)
- Trial name
- NCT04896853
- Testing
- ProTrans®
- Where
- Sweden
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- NextCell Pharma Ab
Severe to Critical COVID 19 With Associated ARDS
A Phase 2/3 Study to Evaluate FP-025 in Patients With Severe to Critical COVID 19
This is a Phase 2/3, randomized, double blind, placebo controlled, multicenter study to evaluate the efficacy and safety of FP-025 in adult patients with severe to critical COVID 19 with associated ARDS.
- Trial name
- NCT04750278
- Testing
- FP-025 100 mg, FP-025 300 mg
- Where
- 8 sites in United States
- Volunteers
- 90 people
- Sponsor
- Foresee Pharmaceuticals Co., Ltd.
Covid-19
Bicentric Study on the Use of ECMO-VV or VA for Severe ARDS Associated With Covid-19
Describes the cohort of patients receiving ECMO-VV or ECMO-VA in the management of severe ARDS refractory to SARS-CoV-2 in the Strasbourg and Louvain centres
- Trial name
- ECMO-SL-CoV-2 (NCT04446286)
- Where
- France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Strasbourg, France
Covid19-associated ARDS, Covid19
A First-in-Human Study of AV-001 in Healthy Subjects
Phase 1 randomized, double-blind, placebo-controlled single ascending dose (SAD) and multiple ascending dose (MAD) first-in-human study in healthy subjects.
- Conditions
- Covid19-associated ARDS, Covid19, ARDS
- Trial name
- NCT04737486
- Testing
- AV-001
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Vasomune Therapeutics, Inc.
Acute Respiratory Distress Syndrome, COVID-19
Polyvalent Immunoglobulin in COVID-19 Related ARds
As of 30/03/2020, 715600 people have been infected with COVID-19 worldwide and 35500 people died, essentially due to respiratory distress syndrome (ARDS) complicated in 25% of the with acute renal failure.
- Trial name
- ICAR (NCT04350580)
- Testing
- Human immunoglobulin
- Where
- 42 sites in France
- Volunteers
- 146 people
- Sponsor
- Centre Hospitalier St Anne
COVID-19 (Coronavirus Disease 2019), COVID-19 Pandemic
University Hospital of Ioannina COVID-19 (Coronavirus Disease 2019) Registry
COVID-19 (Coronavirus Disease 2019) Registry of University Hospital of Ioannina. Retrospective datasource registry with quantitative and qualitative patient data from the hospital medical records.
- Conditions
- COVID-19 (Coronavirus Disease 2019), COVID-19 Pandemic, COVID-19 Pneumonia, COVID-19 Respiratory Infection
- Trial name
- NCT05534074
- Where
- Greece
- Volunteers
- 2,500 people
- Sponsor
- University Hospital, Ioannina
Acute Kidney Injury, COVID-19
Prediction of Acute Kidney Injury in Patients With COVID-19
The two biomarkers determined in urine, "Tissue Inhibitor of Metalloproteinases 2 (TIMP-2)" and "Insulin-like Growth Factor-Binding Protein 7 (IGFBP7)", can indicate the occurrence of Acute kidney injury (AKI) in cardiac surgery…
- Conditions
- Acute Kidney Injury, COVID-19, ARDS
- Trial name
- NCT04406688
- Where
- 13 sites in Germany, Italy and 3 more
- Volunteers
- 300 people
- Sponsor
- University Hospital Muenster